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Abstract
Aims/hypothesis Type 2 diabetes is a bi-hormonal disease
characterised by relative hypoinsulinaemia and hypergluca-
gonaemia with elevated blood glucose levels. Besides
pancreatic beta cell defects, a low number of beta cells
(low beta cell mass) may contribute to the insufficient
secretion of insulin. In this study our aim was to determine
whether the alpha cell mass is also altered.
Methods Using a point counting method, we measured the
ratio of alpha to beta cell areas in pancreas samples
obtained at autopsy from 50 type 2 diabetic subjects, whose
beta cell mass had previously been found to be 36% lower
than that of 52 non-diabetic subjects.
Results The topography of alpha and beta cells was similar
in both groups: many alpha cells were localised in the
centre of the islets and the ratio of alpha/beta cell areas
increased with islet size. The average ratio was significantly
higher in type 2 diabetic subjects (0.72) than in non-
diabetic subjects (0.42), with, however, a large overlap
between the two groups. In contrast, the alpha cell mass
was virtually identical in type 2 diabetic subjects (366 mg)
and non-diabetic subjects (342 mg), and was not influenced
by sex, BMI or type of diabetes treatment.
Conclusions The higher proportion of alpha to beta cells in
the islets of some type 2 diabetic subjects is due to a
decrease in beta cell number rather than an increase in alpha
cell number. This imbalance may contribute to alterations in
the normal inhibitory influence exerted by beta cells on
alpha cells, and lead to the relative hyperglucagonaemia
observed in type 2 diabetes.
Keywords Alpha cell mass.Beta cell mass.Diabetes
pathogenesis.Endocrine pancreas.Glucagon.Insulin
secretion.Islet cells.Pancreatic islets.Type 2 diabetes
Introduction
Hyperglycaemia in type 2 diabetes results from insufficient
and inappropriately sluggish insulin secretion in a context
of diminished insulin action in target tissues [1, 2]. These
secretory defects often coexist with a relatively low beta
cell number, commonly referred to as a decrease in beta cell
mass. On average, this decrease amounted to 30–50% of
normal in postmortem morphological comparisons of
pancreatic samples from non-diabetic and type 2 diabetic
subjects [3–7]. Converging observations also indicate that
the disease is bi-hormonal and entails abnormalities of
glucagon secretion by alpha cells. Type 2 diabetic patients
show excessive plasma glucagon levels for their glycaemia.
This relative hyperglucagonaemia aggravates the conse-
quences of their relative hypoinsulinaemia by activating
glucose production in the liver [8–10].
Inhibition of glucagon secretion by glucose encompasses
direct effects on alpha cells and indirect actions via signals
produced by neighbouring islet cells [11]. Although
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diabetes, dysregulation of glucagon secretion is often
attributed to perturbations in paracrine interactions between
beta and alpha cells [10]. Changes in alpha cell mass could
also underlie such perturbations. Old postmortem studies
using histochemical methods to distinguish beta and alpha
cells have reported that alpha cell mass was unchanged [12]
or decreased by about 35% [13, 14] in maturity onset-
diabetes (type 2 diabetes) when compared with non-diabetic
controls. More recent studies using immunohistochemical
identification of the two cell types have reported that the
relative volume density of alpha cells vs beta cells tended to
be higher [15, 16] or was significantly higher [3, 4, 6, 17–
19] in type 2 diabetic patients than in non-diabetic subjects.
In some of these studies, alpha cell mass could be
calculated and was reported to be decreased by about
45% [16], unchanged [15] or increased by 40–80% [4, 17].
In all of these series, the small number of subjects (2–15
per group) and the high inter-subject variability unfortu-
nately undermine the reliability of certain conclusions. We
have therefore measured alpha cell mass in a larger series of
non-diabetic and type 2 diabetic subjects whose beta cell
mass was reported recently [7].
Methods
Subjects The study, conducted according to the regula-
tions of the local ethics committee, was performed on
pancreatic samples obtained at autopsy (within 12 h of
death) of the subjects in whom we previously measured
beta cell mass [7]. All the 52 non-diabetic subjects could
be studied again, but adequate samples were available from
only 50 of the 57 type 2 diabetic subjects. Omission of
these seven type 2 diabetic subjects had no significant
impact on the conclusions of our previous study. For
instance, beta cell mass averaged 567±248 mg in these 50
type 2 diabetic subjects as compared with 573±259 mg in
the whole group of 57 subjects [7]. Clinical characteristics
of the studied subjects are given in electronic supplemen-
tary material (ESM) Tables 1 and 2.
Pancreas processing, microscopic examination and analysis
of results Pancreatic sections immunostained for insulin
and glucagon were analysed at a final magnification of
×400. The ratio of alpha/beta cell areas was determined by
point counting, using a 100 point lattice [20]. In practice,
the number of points corresponding to alpha cells and beta
cells were counted for each islet in all fields. Small
structures of a few cells were included in the analysis, but
single cells were not counted. The total number of points
(alpha + beta cells) counted in this way averaged 1,794
(696–4,064) in non-diabetic subjects and 1,451 (698–
3,266) in type 2 diabetic subjects. From the measured ratio
of alpha/beta cell areas and the known beta cell mass [7],
the alpha cell mass was calculated (see ESM for further
details on methods).
Presentation of results Most figures show scatter plots of
individual values. As all sets of data passed the Kolmogorov–
Smirnov test of normality, values for non-diabetic and type 2
diabetic groups are presented as means ± SD, and the
differences were assessed by Student’s t test. Comparisons
using a non-parametric Mann–Whitney test yielded similar
levels of significance.
Results
Morphological aspects of the islets Variability in the
cellular composition of islets was evident in the pancreas
of non-diabetic subjects (ESM Fig. 1a–c). Alpha cells
sometimes formed a discontinuous peripheral rim around
the core of beta cells, but were more often localised in the
centre of the islets, usually close to vessels. In some non-
diabetic subjects, large islets with a vast majority of alpha
cells were occasionally observed (ESM Fig. 1c). The inter-
islet variability in the proportions and the topography of
alpha and beta cells was not strikingly altered in the
pancreas of type 2 diabetic subjects (ESM Fig. 1d, e).
However, islets virtually devoid of beta cells (ESM Fig. 1f)
were observed more often than in non-diabetic subjects (see
quantification below).
Ratio of alpha cell to beta cell areas Because the beta cell
volume density is higher in the tail than the body of the
pancreas [7], we first compared specimens from the two
regions. The ratio of alpha/beta cell areas was higher in
the tail of the pancreas in 18/30 non-diabetic subjects,
but mean values were similar (0.437±0.146 vs 0.395±
0.148; NS by paired t test). In type 2 diabetic subjects,
the ratio of alpha/beta cell areas was higher in the tail of
the pancreas in 14/30 subjects, and mean values were not
significantly different. Therefore, individual ratios of
alpha/beta cell areas presented in Fig. 1 are averages of
measurements in the body and tail of the pancreas, when
available, or results of measurements in the body of the
pancreas only.
The ratio of alpha/beta cell areas was variable (∼3×)
between non-diabetic subjects (Fig. 1a). Among type 2
diabetic subjects, one individual showed an extremely
high ratio (3.2) because of a very low (the lowest) number
of beta cells. This extreme value was omitted from further
analyses based on the ratio, except when specified. Even
without this outlier, the ratio of alpha/beta cell areas was
more variable (∼4.6×) among type 2 diabetic than non-
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diabetic than non-diabetic subjects (0.72±0.27 vs 0.42±
0.13; p<0.0001). Note, however, the large overlap
between the two groups (Fig. 1a). The ratio was within
the range of non-diabetic values in 32/50 type 2 diabetic
subjects.
In subsets of 24 subjects, we assessed whether the
ratio of alpha/beta cell areas varied with islet size.
Figure 1b shows that the ratio increased with the size of
the islet profile in non-diabetic subjects: from 0.22±0.09
in the smallest profiles to 0.72±0.34 in the largest ones
(p<0.001). A similar distribution of alpha cells was
observed in islets from type 2 diabetic subjects, so that
the difference between the two groups (∼1.7×) persisted
irrespective of the size of the islet profile (Fig. 1b). In the
same subsets of 24 subjects, we also quantified the visual
impression that islets with a large majority of alpha cells
were more frequent in the pancreas from type 2 diabetic
than non-diabetic subjects. The ratio of alpha/beta cell
areas was ≥3i n6 . 8 ± 5 . 7 %o fi s l e tp r o f i l e si nt y p e2
diabetic subjects, as compared with 2.7±2.1% in non-
diabetic subjects (p<0.005).
In the whole groups of 52 non-diabetic and 50 type 2
diabetic subjects, there was no difference in mean ratios of
alpha/beta cell areas between men and women or between
subjects with a BMI lower or higher than 25 kg/m
2 (Fig. 1c),
but the difference in ratio between non-diabetic and type 2
diabetic subjects remained highly significant (p<0.001) in
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Fig. 1 Ratio of alpha cell/beta cell areas in 52 non-diabetic subjects
(ND) and 50 type 2 diabetic (T2D) subjects. a Scatter plots of ratios
and means ± SD:
†p<0.0001. b Mean ratios ± SD in islet profiles of
increasing sizes. Five classes were defined according to the total
number of points (alpha + beta) counted in each profile: 1–5, 6–10,
11–15, 16–20 and >20. The smallest category corresponds to an area
between 625 and 3,125 μm
2 (6–27 cells) and the largest one to
>12,500 μm
2 (>110 cells). However, these are minimum numbers
because the examined islet profiles also contained structures (vessels,
non-stained cells) that were not counted; white bars, ND; black bars,
T2D. c Mean ratios ± SD in ND and T2D men (n=35 and 26,
respectively) and ND and T2D women (n=17 and 23, respectively)
and in ND and T2D subjects with a BMI below 25 kg/m
2 (n=26 and
13, respectively) or above 25 kg/m
2 (n=26 and 36, respectively):
white bars, ND; black bars, T2D. d Ratio of alpha/beta cell areas as a
function of beta cell mass in ND subjects (white circles; y=0.38+
0.43×10
−4x) and T2D subjects (black circles; y=0.84−0.23×10
−3x)
1722 Diabetologia (2011) 54:1720–1725each category. No correlation was found between the ratio of
alpha/beta cell areas and BMI or age in either non-diabetic or
type 2 diabetic subjects (Table 1) .A ss h o w ni nF i g .1d
(open symbols), the ratio of alpha/beta cell areas was
completely independent of the beta cell mass in non-
diabetic subjects (r=0.100, p=0.48). There was no
significant correlation either in type 2 diabetic subjects
(Fig. 1d, filled symbols; r=−0.204, p=0.16). However, the
highest ratios were often measured in individuals with a
relatively low beta cell mass. Moreover, the negative
correlation became significant (r=−0.333, p=0.02) when
the individual with a very high ratio of alpha/beta cell
areas (3.2 for a beta cell mass of 105 mg) was included in
the analysis.
Alpha cell mass From the ratio of alpha/beta cell areas
measured in this study and the beta cell mass previously
measured in the same subjects [7], we calculated the alpha
cell mass. As shown in Fig. 2a, inter-subject variability was
marked and similar in both groups (∼9×), with almost
identical mean values (347±183 mg in non-diabetic
subjects and 366±186 mg in type 2 diabetic subjects). This
contrasts with the 36% difference in beta cell mass in the
same subjects (Fig. 2b)[ 7]. The alpha cell mass was not
significantly different between men and women. It slightly
decreased with age in non-diabetic subjects but not in type 2
diabetic subjects, and was not correlated with BMI in either
group (Table 1). There was a strong (p<0.0001) correlation
between the alpha cell mass and the beta cell mass in both
groups (r=0.725 in non-diabetic subjects and r=0.664 in
type 2 diabetic subjects) (Fig. 2c).
Figure 2d compares the relative alpha cell and beta cell
masses in the different groups. The mass ratio was
virtually identical (0.39) in lean and overweight non-
diabetic subjects. It was similarly augmented (between 0.6
and 0.7) in lean and overweight/obese type 2 diabetic
subjects, regardless of their treatment by oral drug or
insulin.
Discussion
We report that the average pancreatic alpha cell mass is
similar in a series of 52 non-diabetic subjects and 50 type 2
diabetic subjects. However, owing to the ∼36% decrease in
beta cell mass in these type 2 diabetic subjects, their alpha
cell/beta cell mass ratio is increased ∼1.7× compared with
non-diabetic subjects.
The proportion of alpha and beta cells in human islets
has previously been determined, usually in small numbers
of islets from limited numbers of non-diabetic subjects.
When identified nucleated cells were counted in isolated
islets or in islets in situ, the ratio of alpha/beta cell numbers
ranged from 0.37 to 0.55 [18, 21–23]. When alpha/beta cell
areas were measured by semi-automatic imaging pro-
grammes, the ratio ranged from 0.24 in isolated islets [24]
to 0.56 in islets in situ [19]. Using a point counting method
to examine islets in situ, we measured an average ratio of
alpha/beta cell areas of 0.42 in 52 non-diabetic subjects.
This value is in the upper range of previous measurements
by point counting (0.28–0.44) in smaller series [4, 6, 16,
17]. It is important to underline that measurements of
relative cell area do not adequately reflect relative cell
numbers because alpha cells are smaller than beta cells
[25]. Our measurements therefore underestimate the ratio of
alpha/beta cell numbers but, unlike the latter, permit the
correct calculation of alpha cell mass.
Recent studies focusing on the topography of the
different cell types in islets have emphasised that, in
contrast to rodent islets, the majority of alpha cells do not
form a peripheral rim in normal human islets, but are
concentrated in the centre [21–24] in close proximity to
vessels [19]. Our observations agree with these descrip-
tions. Moreover, our analysis of 100–300 islet profiles in
each of 30 pancreas samples shows that the ratio of alpha/
beta cell areas increases with apparent size of the islet,
providing further quantitative support to previous conclu-
sions [19] that alpha cells are preferentially localised in the
Variable Non-diabetic subjects (n=52) Type 2 diabetic subjects (n=50)
rp value rp value
Ratio alpha/beta cell areas vs
Age −0.234 0.096 0.068 0.644
BMI 0.026 0.858 −0.145 0.319
Alpha cell mass vs
Age −0.361 0.009 −0.150 0.300
BMI 0.224 0.111 −0.079 0.584
Beta cell mass
a vs
Age −0.278 0.046 −0.218 0.128
BMI 0.341 0.013 0.311 0.028
Table 1 Correlation between
the ratio of alpha/beta cell
areas, alpha cell mass or beta
cell mass, and age or BMI, in
non-diabetic and type 2 diabetic
subjects
aValues for beta cell mass are
taken from Rahier et al. [7]
Diabetologia (2011) 54:1720–1725 1723centre of large islets and in the mantle region of small islets.
The reason why the proportion of alpha cells increases with
the size of the islet [6, 19] is not known, but this variation
may complicate comparisons of data obtained in different
studies if not all sections of islets are counted. Most
importantly, we have also established that this relative
distribution of alpha and beta cells is not perturbed in islets
from type 2 diabetic subjects: the proportion of alpha cells
also increases with the size of the islet profile, so that the
difference between diabetic samples and controls is not
restricted to one particular islet category.
Beta cell mass slightly increases with BMI in non-
diabetic subjects [5–7]. This increase is usually viewed as
an adaptation to greater insulin needs to overcome the
resistance of peripheral tissues. It was therefore unexpected
that the ratio of alpha/beta cell areas did not decrease with
the increase in BMI. We have no explanation, but wish to
point out that beta cell mass was only 20% higher (972 vs
804 mg) in our group of overweight non-diabetic subjects
(mean BMI 30 kg/m
2, no individual >40 kg/m
2) than in our
group of lean non-diabetic subjects (mean BMI 22 kg/m
2)
[7]. It is also notable that ageing was accompanied by a
small decrease of both alpha and beta cell mass in non-
diabetic subjects.
From our measurements, we can conclude that the relative
hyperglucagonaemia of type 2 diabetic subjects is not the
consequence of an increased alpha cell mass. The elevated
ratio of alpha/beta cell areas measured in the pancreas of these
subjects is attributable to the decrease in beta cell number [7].
If alpha cell function is controlled by direct contact between
the two cell types or by products released by beta cells
(insulin or others), and reaching alpha cells via either a
paracrine route or the islet microvasculature, perturbations of
glucagon secretion may obviously result from the lower
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Fig. 2 a Alpha cell mass in the pancreas of 52 non-diabetic (ND)
subjects and 50 type 2 diabetic (T2D) subjects. Scatter plot and means ±
SD. b Beta cell mass in the pancreas of the same subjects; data taken
from Rahier et al. [7] with slight modifications; ***p<0.001.
c Correlations between alpha cell mass and beta cell mass in ND
subjects (white circles; y=−42+0.44x) and T2D subjects (black circles;
y=86+0.49x). d Ratio of alpha cell mass to beta cell mass in ND
subjects with a BMI <25 (n=26) and >25 (n=26) kg/m
2, and in T2D
subjects subdivided according to treatment (drug or insulin) and BMI
(n=8, 16, 5, 20 from left to right)
1724 Diabetologia (2011) 54:1720–1725relative number of beta vs alpha cells. This may be
particularly true in the generally large islets quasi-
exclusively composed of alpha cells. However, qualitative
and quantitative relationships between both cell types are not
consistently perturbed in all islets from all type 2 diabetic
subjects. Some type 2 diabetic individuals have beta and
alpha cell masses similar to those of non-diabetic individuals.
One insurmountable limitation in the interpretation of our
results, obtained from autopsy specimens, is the impossibility
of correlating the extent of dysregulation of glucagon
secretion with changes in the cellular composition of islets.
In the absence of changes in islet cell numbers, relative
hyperglucagonaemia might be secondary to functional per-
turbations of beta cells [10] or intrinsic defects of alpha cells.
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